Treatment News : FDA OKs Major New Hepatitis C Drug, Sovaldi (Sofosbuvir)

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » December 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


December 6, 2013

FDA OKs Major New Hepatitis C Drug, Sovaldi (Sofosbuvir)

The U.S. Food and Drug Administration has approved Gilead Sciences’ hotly anticipated Sovaldi (sofosbuvir), a once-daily oral nucleotide analog polymerase inhibitor to treat people with hepatitis C virus (HCV), including those coinfected with HIV and those who have liver cancer and are awaiting a transplant. For those with genotypes 2 and 3 of the virus, Sovaldi offers the first-ever opportunity for treatment with an interferon-free drug regimen. Those with genotypes 1 and 4, however, will in most cases still require the injectable interferon, which causes flu-like side effects.

Sovaldi must be taken in combination with ribavirin regardless of genotype. The recommended treatment duration is 12 weeks for genotypes 1, 2 and 4, and 24 weeks for genotype 3.

Gilead also states that those with genotype 1 who are ineligible to take interferon "can be considered" to receive Sovaldi and ribavirin for 24 weeks of treatment. Also, for those awaiting a liver transplant, the same combination should be given for up to 48 weeks before transplantation to prevent post-transplant infection with the virus.

“Today’s approval represents a significant shift in the treatment paradigm for some patients with chronic hepatitis C,” Edward Cox, MD, director of the office of antimicrobial products in the FDA’s center for drug evaluation and research, said in a release.

A four-week supply of Sovaldi will cost $28,000. For the same supply, the price tag for Janssen’s NS3/4A protease inhibitor Olysio (simeprevir), which the FDA approved on November 22, will be $22,120.

Sovaldi leads the pack in the race for highly effective all-oral, interferon- and even ribavirin-free hep C therapies, and many expect the drug to become a major blockbuster. The release of Sovaldi and Olysio, however, is really only a warm-up round. The real clincher won’t come until late 2014 when the crucial NS5A inhibitors will likely hit the market. Gilead is hoping to gain approval for a single, coformulated pill of Sovaldi and the company’s NS5A inhibitor ledipasvir, which has boasted near-perfect cure results in recent trials.

In the meantime, physicians may choose to prescribe Sovaldi off-label in combination with Olysio. Phase II studies of the pair, given both with and without ribavirin, have yielded cure rates in the mid-90 percent range.

“Today marks a landmark advance in the treatment of hepatitis C, opening up new opportunities to stop the spread of this virus and the ravages of this disease,” John Ward, MD, director of the Centers for Disease Control and Prevention’s (CDC) division of viral hepatitis, said in a release. “However, new therapies only work if people receive treatment—the potential of these and other treatment advances hinges entirely on our ability to get more people screened and into care. Right now, most Americans with hepatitis C don’t access treatment because they have no idea they’re infected.”

The FDA’s approval of Sovaldi was based on data from four Phase III studies, NEUTRINO, FISSION, POSITRON and FUSION. Between 50 and 90 percent of study participants taking Sovaldi-based treatments achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure).

Sovaldi has proved well tolerated, with typically mild adverse events among study participants and few treatment discontinuations because of side effects. The most common adverse side effects, found in at least one in five of participants taking Sovaldi with ribavirin and interferon, were fatigue, headache, nausea, insomnia and anemia.

To read the Gilead release, click here.

To read the FDA release, click here.

To read a recent feature on the hep C treatment landscape, which includes greater detail on research mentioned in this article, click here.

Search: Hepatitis C virus, hepatitis C, hep C, HCV, Gilead Sciences, sofosbuvir, Sovaldi, HIV, transplant, liver cancer, interferon, ribavirin, Edward Cox, U.S. Food and Drug Administration, FDA, approval, Olysio, simeprevir, cost, ledipasvir, John Ward, NEUTRINO, FISSION, POSITRON, FUSION, cure.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

  comments 16 - 24 (of 24 total)     << < previous

Dr Erum Rehman, Dubai, 2014-02-05 02:54:29
i want to use this for a female pt age 59 with diabetes wellc ontrolled genotype 4 failed 2 previous courses can u tell me the correct regimen with ribavarin and interferon dosing and duration

Jenn, , 2014-01-15 04:33:06
The fact that they're charging $1,000 per tablet due to what they think the "value to market" is, is ridiuculous. Not only that, but they offer a $5 coupon card on their website! If you can offer a $5 coupon card for your own product, but charge insurance $28,000 there is something very wrong

robert belanger, laval, 2014-01-11 21:06:23
I had a transplant of my liver 2 years ago. right the doctor tell me that the desease is back in my liver and I am stage 2. it is great news BUT who can afford the cost of $84000.00

Koumte Mamgodibaye, Cold lake, 2013-12-20 19:46:41
Can sofosbuvir be used for Hepatitis B please?

Ben Ryan, NYC, 2013-12-10 10:27:42
For those who are concerned that the price of Sovaldi treatment may be out of reach, check out Gilead's patient assistance program at

Abdelrahman Sharaf, HOUSTON, 2013-12-09 18:45:25

Chris, , 2013-12-09 08:39:20
I was in the study group for the research testing of this drug. Let me say this...this drug, and others like it are nothing short of miracles. I had no side effects, short treatment term, and quick response time. These drugs will revolutionize the treatment of Hep C, especially for co-infected patients. My hope is that eventually the price tag of these drugs will come down, I was blessed enough to be in a study and my medication was provided for free, but $28,000 is large price to pay.

bassem sadek, Egypt, 2013-12-08 04:05:33
What about a lady dedicated her life for her kids and she cannot buy sovaldi due to the expensive price and she suffering from genotype 4 badly may be she dies if no one help. is there is anyone out there can help her? I hope so & god bless her.

Mohammad Afzal, Islamabad Pakistan, 2013-12-07 10:59:03
The cost of the this cure is beyond our reach. Is there a way a poor person can access this cure?? When will it be available in third world countries?

comments 16 - 24 (of 24 total)     << < previous

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.